Should I buy or sell H. Lundbeck A/S stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for H. Lundbeck A/S in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" HLUYY shares. View HLUYY analyst ratings or view top-rated stocks .

How have HLUYY shares performed in 2024?

H. Lundbeck A/S's stock was trading at $22.00 at the start of the year. Since then, HLUYY shares have increased by 0.0% and is now trading at $22.00. View the best growth stocks for 2024 here .

How were H. Lundbeck A/S's earnings last quarter?

H. Lundbeck A/S (OTCMKTS:HLUYY) announced its quarterly earnings results on Wednesday, November, 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.16. The business had revenue of $547.05 million for the quarter, compared to analyst estimates of $514.82 million. H. Lundbeck A/S had a trailing twelve-month return on equity of 13.74% and a net margin of 6.74%.

Is H. Lundbeck A/S a good dividend stock?

H. Lundbeck A/S (OTCMKTS:HLUYY) pays an annual dividend of $0.20 per share and currently has a dividend yield of 0.91%. The dividend payout ratio is 22.73%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, HLUYY will have a dividend payout ratio of 7.02% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for HLUYY .

How do I buy shares of H. Lundbeck A/S?

Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does H. Lundbeck A/S have any subsidiaries?

The following companies are subsidiares of H. Lundbeck A/S: Alder BioPharmaceuticals, and Prexton Therapeutics. Read More

OTCMKTS:HLUYY

H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free HLUYY Stock Alerts

$22.00

-0.01 (-0.02%)

(As of 08/9/2022)

Compare

Today's Range: $22.00
▼
$24.00
50-Day Range: $22.00
▼
$22.00
52-Week Range: $10.00
▼
$31.55

Volume: 7,500 shs
Average Volume: 1,758 shs
Market Capitalization: $21.91 billion

P/E Ratio: 25.00
Dividend Yield: 0.91%
Price Target: N/A

Stock Analysis

Get H. Lundbeck A/S alerts:

Ad Crypto Swap Profits

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

About H. Lundbeck A/S Stock (OTCMKTS:HLUYY)

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

HLUYY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HLUYY Stock News Headlines

April 18, 2024 | americanbankingnews.com

H. Lundbeck A/S (OTCMKTS:HLUYY) Stock Price Passes Below Fifty Day Moving Average of $22.00

April 16, 2024 | finance.yahoo.com

H. Lundbeck A/S (LDBB.F)

April 19, 2024 | InvestorPlace (Ad)

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 15, 2024 | msn.com

‘Vanished’: 25 years since Nathan Edberg’s vehicle was found abandoned in Vadnais Heights, search for answers continues

March 25, 2024 | fool.com

H. Lundbeck A/s (OTC: HLUYY)

February 23, 2024 | investing.com

H Lundbeck A/S ADR (HLUYY)

February 11, 2024 | msn.com

WWE: Becky Lynch gives fans a preview of what to expect from her book

January 19, 2024 | msn.com

A Chilling New Twist in the Lindbergh Baby Mystery Could Actually Flip the Verdict

April 19, 2024 | InvestorPlace (Ad)

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

August 23, 2023 | wsj.com

H. Lundbeck A/S Cl A

August 11, 2023 | msn.com

‘Finding W.H. Hudson’ Review: The Enigmatic Birdman

August 8, 2023 | nytimes.com

To Have and to Hold, Even if You Turn Into a Literal Shark

July 18, 2023 | uk.investing.com

H Lundbeck B (0ND5)

May 12, 2023 | msn.com

H. Lundbeck A/S reports Q1 results

February 8, 2023 | msn.com

H. Lundbeck A/S reports FY results

November 24, 2022 | finance.yahoo.com

H. Lundbeck A/S (HLUN-B.CO)

October 20, 2022 | investing.com

H Lundbeck B (HLUNb)

September 14, 2022 | msn.com

Monica Lewinsky's Response to Death of Clinton Prosecutor Ken Starr Praised

September 13, 2022 | msn.com

Watch Lucid's Boss Spend an Hour Explaining How the Air's Motor Works

September 9, 2022 | msn.com

Everyone's Saying The Same Thing About Odell Beckham Jr. Tonight

September 6, 2022 | msn.com

Slain Memphis jogger Eliza Fletcher was a 2010 graduate of Baylor University

September 3, 2022 | msn.com

Former Lutz Children’s Museum director busted on child pornography charges

September 2, 2022 | yahoo.com

Former children’s museum director pleads guilty to child pornography charges

September 2, 2022 | msn.com

Former executive director for Manchester children's museum pleads guilty to distributing child pornography

September 1, 2022 | news.yahoo.com

Former Lutz Children's Museum director admits distributing child porn

August 31, 2022 | finance.yahoo.com

Ruben Östlund Remembers ‘Triangle of Sadness’ Actress Charlbi Dean: ‘A Shock and a Tragedy’

June 25, 2022 | businessinsider.com

EV startup Lucid froze its assembly line for a week in early June amid its ongoing struggle to ramp up production

See More Headlines

Receive HLUYY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2015
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Private Households
Sub-Industry: N/A
Current Symbol: OTCMKTS:HLUYY
CUSIP: N/A
CIK: N/A
Web: www.lundbeck.com
Phone: (453) 630-1311
Fax: 45-3630-1940
Employees: 5,348
Year Founded: 1915

Profitability

EPS (Most Recent Fiscal Year): $0.88
Trailing P/E Ratio: 25.00
Forward P/E Ratio: 10.48
P/E Growth: N/A
Net Income: $209.69 million
Net Margins: 6.74%
Pretax Margin: 7.83%
Return on Equity: 13.74%
Return on Assets: 7.16%

Debt

Debt-to-Equity Ratio: 0.32
Current Ratio: 1.15
Quick Ratio: 0.71

Sales & Book Value

Annual Sales: $2.59 billion
Price / Sales: 8.45
Cash Flow: $3.36 per share
Price / Cash Flow: 6.54
Book Value: $14.60 per share
Price / Book: 1.51

Miscellaneous

Outstanding Shares: 995,741,000
Free Float: N/A
Market Cap: $21.91 billion
Optionable: Not Optionable
Beta: 0.68

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Deborah Dunsire M.D. (Age 60)
Pres & CEO
Comp: $7.16M
Mr. Jacob Tolstrup (Age 50)
Exec. VP of Commercial Operations & Chief Commercial Officer
Comp: $888.17k
Mr. Lars Bang (Age 60)
Exec. VP of Product Devel. & Supply
Comp: $915.5k
Dr. Per Johan Luthman (Age 63)
Exec. VP of R&D
Comp: $901.84k
Mr. Bjorn R. Mogensen
Sr. VP Group Fin.
Dr. Tarek Samad Ph.D.
Sr. VP & Head of Research
Mr. Palle Holm Olesen
Chief Specialist & VP of Investor Relations
Ms. Elise Hauge (Age 55)
Exec. VP of People & Communication
Mr. Ole Chrintz (Age 64)
Sr. VP of International Markets
Mr. Keld Flintholm Jorgensen (Age 51)
Exec. VP of Corp. Strategy & Bus. Devel.

Key Competitors

View All Competitors

Should I Buy H. Lundbeck A/S Stock? HLUYY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in H. Lundbeck A/S:

H. Lundbeck A/S has a diverse portfolio of pharmaceutical products targeting psychiatric and neurological disorders, providing a wide range of revenue streams.
The company's recent partnership agreements and collaborations indicate a focus on innovation and potential for future growth.
With the introduction of Vyepti for migraine prevention, H. Lundbeck A/S has expanded its product offerings into a high-demand therapeutic area.
Investors may find the company's focus on real-world evidence in support of migraine therapy promising for market differentiation and potential market share growth.
Current stock price of HLUYY is showing a positive trend, indicating potential value appreciation for investors.

Cons

Investors should be bearish about investing in H. Lundbeck A/S for these reasons:

The competitive landscape in the pharmaceutical industry can pose challenges for market share and pricing pressures.
Regulatory uncertainties and changes in healthcare policies could impact the company's product development and market access.
Dependency on a few key products for a significant portion of revenue may expose the company to risks associated with product lifecycle and patent expirations.
Fluctuations in currency exchange rates can affect the company's financial performance, especially in international markets.
Market volatility and macroeconomic factors may influence investor sentiment towards the company's stock.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these H. Lundbeck A/S pros and cons to contact@marketbeat.com.

HLUYY Stock Analysis - Frequently Asked Questions

Should I buy or sell H. Lundbeck A/S stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for H. Lundbeck A/S in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" HLUYY shares.
View HLUYY analyst ratings or view top-rated stocks.
How have HLUYY shares performed in 2024?: H. Lundbeck A/S's stock was trading at $22.00 at the start of the year. Since then, HLUYY shares have increased by 0.0% and is now trading at $22.00.
View the best growth stocks for 2024 here.
How were H. Lundbeck A/S's earnings last quarter?: H. Lundbeck A/S (OTCMKTS:HLUYY) announced its quarterly earnings results on Wednesday, November, 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.16. The business had revenue of $547.05 million for the quarter, compared to analyst estimates of $514.82 million. H. Lundbeck A/S had a trailing twelve-month return on equity of 13.74% and a net margin of 6.74%.
Is H. Lundbeck A/S a good dividend stock?: H. Lundbeck A/S (OTCMKTS:HLUYY) pays an annual dividend of $0.20 per share and currently has a dividend yield of 0.91%. The dividend payout ratio is 22.73%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, HLUYY will have a dividend payout ratio of 7.02% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for HLUYY.

How do I buy shares of H. Lundbeck A/S?: Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does H. Lundbeck A/S have any subsidiaries?: The following companies are subsidiares of H. Lundbeck A/S: Alder BioPharmaceuticals, and Prexton Therapeutics.
Read More

This page (OTCMKTS:HLUYY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial